Skip to main content
Home > eLearning > White Papers
eLearning Center
The content listed below is submitted by our sponsors.
Featured White Paper

Key Account Management Strategies for Biotech, Med Device & Pharma

Posted on: July 23, 2014
By: Healthcare Data Solutions

A one-size-fits-all approach to new customers won't work in today's dynamic healthcare landscape. Companies that want to thrive must move away from the buyer-seller model and head toward key account management.

In this free whitepaper, you'll discover:

Why Key Account Management is crucial in healthcare
How to overcome common barriers to KAM
Skills that every Key Account Manager needs
New rules and new tools for marketing & sales
2014 Dealmakers' Intentions Study

Posted: June 30, 2014
By: Campbell Alliance

Now in its sixth year, the Campbell Alliance Dealmakers’ Intentions Study is the only forward-looking measure of dealmaking activity in the pharmaceutical and biotech industries.  While there are many quality sources of information that look historically at past deal trends, this survey offers a prospective view of the partnering and licensing landscape for the year ahead.

In the first quarter of 2014, Campbell Alliance surveyed 99 licensing professionals, capturing expectations for deal activity, supply and demand for assets at different stages of development, and approaches to valuation. The results of that survey provide a forward-looking view into what dealmakers anticipate will happen in licensing and acquisitions over the upcoming year. The results of the 2014 Dealmakers’ Intentions Study suggest a narrowing of the discount rate, coupled with a strong IPO market, contributing to tempered optimism for M&A/licensing deal activity looking forward into the second half of 2014. The market for dealmaking appears to be softening, and, as such, both buyers and sellers are likely going to need to modify their approach given the potential headwinds.


L.E.K. Strategic Hospitals Priorities Study: Hospitals Look to MedTech for New Services and Solutions

Posted: March 10, 2014
By: L.E.K. Consulting

In its fifth annual hospital priorities study, L.E.K. Consulting examines what hospital CEOs and other senior decision makers believe are the major challenges to the MedTech industry and their institutions. As they look to improve profitability and at least maintain patient quality, executives report that hospital systems are initiating four broad measures: consolidating to improve leverage with payers and suppliers; integrating with alternative care facilities to offer a fuller continuum of care; becoming more accountable in order to take advantage of emerging reimbursement models; and centralizing and coordinating supply chains. While the final measure may frighten some MedTech executives, it presents opportunities for companies that can reposition themselves to offer broader solutions to hospital systems. The fifth annual L.E.K. Hospital Priorities Study explores how MedTech companies can thrive in this new environment.


4 Tips to identify the right FSP partner

Posted: April 7, 2014
By: Rho World

Functional service provider (FSP) partnerships have been gaining traction in recent years because of their potential for increasing efficiency in outsourcing without compromising quality. Rho World has been supporting sponsors in this model for more than a decade, so they understand the common hurdles and how to avoid them. Learn about seemless integration of biostatistics and statistical programming, CDISC and data standards, clinical data management and regulatory medical writing.


MoFo BioMeter

Posted: April 4, 2013
By: Morrison & Foerster

MoFo BioMeter reports a robust 2013 for biotech licensing deals. Aided by a healthy surge in Q4 transactions, up-front payments for licensing deals for all of 2013 increased more than 60% from 2012, averaging $33.9 million. New in this issue is a survey of 2013 biotech hot spots which shows San Francisco on top followed by the Mid-Atlantic region, New York/New Jersey and San Diego, with Germany the international leader.


The Case for Standards

Posted: March 3, 2014
By: The Global Biological Standards Institute

Recent mainstream media, scientific literature, and even NIH have expressed serious concerns over the state of R&D methodologies in life science research. The Global Biological Standards Institute (GBSI) commissioned a 3rd party organization to assess the quality of these R&D methodologies, and through 60 stakeholder interviews, found that irreproducibility is a pervasive, systemic problem that profoundly affects the entire research community. The Case for Standards in Life Science Research identifies a variety of factors that contribute to this irreproducibility crisis, but overall, most can be traced to the absence of a unifying framework of standards — from systems, processes, and procedures to standardized reference materials. Standards have driven innovation in every field of science and technology from Wi-Fi to building bridges, but there are few broadly implemented standards in the life sciences. The Case for Standards lays out a plan for how a standards framework can transform biological research.


Biologics Inflection Point: Managing Risk From Biosimilar Competition

Posted: April 23, 2014
By: L.E.K. Consulting

In this Executive Insights, L.E.K. Consulting argues that the future success of blockbuster branded biologics hinges on the response of three key stakeholder groups who will play a role in biosimilar adoption—prescribers, patients and payers. Examining these stakeholders in detail, the authors explore a subset of strategies for engagement which underpin an enhanced ability to compete and win in this new and challenging market landscape.


The Future Policy Landscape for Emerging Biotechnology Companies: A Guide to Promising Policies Shaping the Future of the Biotech Industry

Posted: December 31, 2013
By: Biotechnology Industry Organization

Innovative biotech companies at all stages of the development process are working toward next generation technologies to heal, fuel, and feed the world. Many research-intensive companies rely on private investment to support their groundbreaking R&D. Because of the long research process intrinsic to scientific advancement, growing innovators operate without product revenue and thus cannot use the sale of one product to finance the development of another. The investment dollars that fund the decade-long, billion-dollar biotech pipeline are supporting the next generation of breakthrough technologies. BIO’s whitepaper, The Future Policy Landscape for Emerging Biotechnology Companies: A Guide to Promising Policies Shaping the Future of the Biotech Industry, highlights key legislation that could impact the sector in the future.


4 Key Considerations for Digital Signatures in the Life Sciences Industry

Posted: January 23, 2014
By: ARX

As life sciences professionals move toward automation in order to improve operational efficiency, they must consider a secure and compliant solution for obtaining signatures. Without one, they are forced to revert to paper each time the need for a signature arises, creating process delays and hindering efficiency and collaboration. In this white paper, you'll gain four key insights that will help set you on the right path toward a proper digital signature solution for your organization.


Managing the Complexities of Global Pharmaceutical Sourcing

Posted: December 31, 2013
By: DPT Labs

With the increased globalization and complexity of the pharmaceutical supply chain, managing the sourcing of materials has become extremely challenging. Reducing time and costs are important goals of sourcing, but increased regulations and more rigorous enforcement make these goals difficult to achieve. With appropriate resources and systems in place to manage these issues, CDMOs such as DPT Laboratories offer a turnkey approach to control costs, avoid disruptions and ensure quality across the supply chain.

BioCentury This Week Television SciBX: Science Busines eXchange